Task
User Exploration of CatenaBio's Offerings
As a potential customer interested in innovative biotech solutions, I understand CatenaBio's company background and scientific approach, so that I can evaluate whether their offerings align with my needs and interests in antibody-drug conjugate technologies.
Success definition: Given I am on the CatenaBio homepage When I navigate through the company's About Us, Science, and Pipeline pages Then I should see comprehensive information about CatenaBio's mission, scientific approach, and current projects in antibody-drug conjugate technology.
Trajectory
Step 1:
Url (before/after):
https://catenabio.com/
https://catenabio.com/about-us/
Content (before/after):
RootWebArea Home - CatenaBio, focused, url='https://catenabio.com/'
banner
paragraph
StaticText Alert:
StaticText Unauthorized individuals have been falsely claiming to represent CatenaBio.
Show more
[60] link Learn more, center=(1324,30), inner_text=Learn more , url='https://catenabio.com/contact#alert'
[64] link CatenaBio Home, center=(193,94), url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo.svg'
link Skip to content, url='https://catenabio.com/#content'
[71] link Contact Us, center=(1782,94), url='https://catenabio.com/contact/'
navigation
list
listitem
[91] link About Us, center=(390,158), url='https://catenabio.com/about-us/'
listitem
[93] link Science, center=(625,158), url='https://catenabio.com/science/'
listitem
[95] link Pipeline, center=(854,158), url='https://catenabio.com/pipeline/'
listitem
[97] link Investors + Partners, center=(1139,158), url='https://catenabio.com/investors-partners/'
listitem
[99] link News + Publications, center=(1481,158), url='https://catenabio.com/news-publications/'
heading Next-Generation Protein Conjugation
paragraph
StaticText At CatenaBio, we envision a future where therapeutics are limited only by imagination.
image, url='https://catenabio.com/wp-content/themes/catena/images/blue-logo-dist-home.png'
heading Because sometimes biology isn’t enough.
heading Building with biologics should be as easy as building with small molecules.
paragraph
StaticText Today, we can't make the medicines we’d like to, because current approaches to building biologic structures are limited.
[125] link About CatenaBio, center=(179,1076), url='https://catenabio.com/about-us/'
paragraph
StaticText Imagine if you could:
heading Take any antibody-drug conjugate (ADC) and add additional therapeutic modalities
heading Take any antibody and attach functional cytokines
heading Attach a targeting protein to the surface of any cell without genetic editing
heading Breakthrough Protein Conjugation
paragraph
StaticText CatenaBio’s
StaticText CysTyr
superscript
StaticText ™
StaticText platform utilizes the novel
StaticText Catenase
superscript
StaticText ™
StaticText enzyme, which catalyzes the formation of our proprietary
StaticText C-Y Bond
superscript
StaticText ™
StaticText using only
StaticText native amino acids
StaticText .
paragraph
StaticText Our approach eliminates the current size and complexity constraints that restrict molecule connections. This allows attachment of multiple different cargoes to a protein, delivering new therapeutic modalities.
paragraph
StaticText All this is accomplished with greater
StaticText speed
StaticText ,
StaticText stability
StaticText ,
StaticText selectivity
StaticText , and
StaticText scalability
StaticText than current approaches.
link Explore the science, url='https://catenabio.com/science/'
image A molecule with an inactivated n- or c-terminal tyrosine., url='https://catenabio.com/wp-content/themes/catena/images/science-mol-1.svg'
image A molecule conjugated with a second molecule using the C-Y bond, url='https://catenabio.com/wp-content/themes/catena/images/molecule-link-1.svg'
heading Exceptional Minds Exceptional Innovation
paragraph
StaticText Our team has been instrumental in advancing medical research. Our technology was developed in the same halls where CRISPR was born, a connection that fuels our passion for pushing the boundaries of scientific discovery.
link Meet our team, url='https://catenabio.com/about-us/#team'
image, url='https://catenabio.com/wp-content/themes/catena/images/yellow-logo-dist.svg'
heading Our Pipeline: Transforming the ADC Market Through Revolutionary Multi-Payload Conjugate™ Technology
superscript
link View our pipeline, url='https://catenabio.com/pipeline/'
image CatenaBio News, url='https://catenabio.com/wp-content/themes/catena/images/catena-bio-news.svg'
heading CatenaBio Presents Poster on Multi-Payload Conjugates at the American Association for Cancer Research (AACR) Annual Meeting
paragraph
StaticText April 8, 2024
StaticText |
StaticText San Diego, CA
link, url='https://catenabio.com/news/catenabio-presents-poster-on-multi-payload-conjugates-at-the-american-association-for-cancer-research-aacr-annual-meeting/'
heading CatenaBio Selected to Present on its Next Generation Platform and Multi Payload Conjugates (MPC®) at the Berkeley Bio Startup Showcase @JPM
paragraph
StaticText January 4, 2024
StaticText |
StaticText Berkeley, CA
link, url='https://catenabio.com/news/catenabio-selected-to-present-jpm-2024/'
heading Building Platform and Partnerships
link Collaborate with us, url='https://catenabio.com/investors-partners/'
contentinfo
link CatenaBio Home, url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo-white.svg'
link, url='https://www.linkedin.com/company/catena-biosciences/'
link About Us, url='https://catenabio.com/about-us/'
link Science, url='https://catenabio.com/science/'
link Pipeline, url='https://catenabio.com/pipeline/'
link Investors + Partners, url='https://catenabio.com/investors-partners/'
link News + Publications, url='https://catenabio.com/news-publications/'
link Privacy Policy, url='https://catenabio.com/privacy-policy/'
link Terms + Conditions, url='https://catenabio.com/terms-conditions/'
link Contact Us, url='https://catenabio.com/contact/'
paragraph
StaticText Catenase, CysTyr, C-Y Bond, and Multi-Payload Conjugate are trademarks of CatenaBio. Other trademarks are property of their respective owners.
paragraph
StaticText © 2025 CatenaBio. All Rights Reserved.
RootWebArea About Us - CatenaBio, focused, url='https://catenabio.com/about-us/'
banner
paragraph
StaticText Alert:
StaticText Unauthorized individuals have been falsely claiming to represent CatenaBio.
Show more
[58] link Learn more, center=(1324,30), inner_text=Learn more , url='https://catenabio.com/contact#alert'
[62] link CatenaBio Home, center=(193,94), url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo.svg'
link Skip to content, url='https://catenabio.com/about-us/#content'
[69] link Contact Us, center=(1782,94), url='https://catenabio.com/contact/'
navigation
list
listitem
[89] link About Us, center=(392,161), url='https://catenabio.com/about-us/'
listitem
[91] link Science, center=(629,158), url='https://catenabio.com/science/'
listitem
[93] link Pipeline, center=(857,158), url='https://catenabio.com/pipeline/'
listitem
[95] link Investors + Partners, center=(1141,158), url='https://catenabio.com/investors-partners/'
listitem
[97] link News + Publications, center=(1482,158), url='https://catenabio.com/news-publications/'
heading Game-Changing Biomolecule Synthesis
paragraph
StaticText Developed in the same halls where CRISPR was created, CatenaBio’s technology enables the fusion of proteins with the 3-dimensional control that only previously existed with small molecule synthesis. The result is the ability to synthesize novel biomolecules in any structure, combination, or orientation—the only limitation is imagination.
paragraph
StaticText We foresee the impact of our bioconjugation approach extending across therapeutic areas; it may even have consumer applications.
paragraph
StaticText The core of CatenaBio’s technology results from an exhaustive search of the microbial kingdom for a robust enzyme with broad effectiveness. The patented Catenase
superscript
StaticText ™
StaticText technology enables biomolecules to be fused at naturally occurring amino acids—tyrosine and cysteine—under gentle reaction conditions that optimize novel biomolecule yield.
image, url='https://catenabio.com/wp-content/themes/catena/images/blue-yellow-logo-dist-rec.svg'
heading Originating From Berkeley Labs
paragraph
StaticText Our science is invented by the top minds at UC Berkeley
image, url='https://catenabio.com/wp-content/themes/catena/images/jennifer-doudna.png'
heading Professor Jennifer Doudna, PhD
heading Inventor | 2020 Nobel Prize Laureate – Chemistry
image, url='https://catenabio.com/wp-content/themes/catena/images/matt-francis-final.png'
heading Professor Matt Francis, PhD
heading Inventor | Chair of the UC Berkeley Department of Chemistry
heading Meet the Visionaries Behind the Science
heading Leadership Team
image, url='https://catenabio.com/wp-content/themes/catena/images/team/final/saurabh-johri.png'
heading Saurabh Johri
paragraph
StaticText Chief Business Officer
image, url='https://catenabio.com/wp-content/themes/catena/images/team/final/rick-kendall.png'
heading Rick Kendall, PhD
paragraph
StaticText Chief Science Officer
image, url='https://catenabio.com/wp-content/themes/catena/images/team/final/marco-lobba.png'
heading Marco Lobba, PhD
paragraph
StaticText CEO and Co-founder
heading Scientific Advisors
image, url='https://catenabio.com/wp-content/uploads/2023/10/matt-francis-final.png'
heading Matt Francis, PhD
heading
image, url='https://catenabio.com/wp-content/uploads/2023/09/john-delaney.png'
heading John Delaney, PhD
heading
image, url='https://catenabio.com/wp-content/uploads/2023/09/marc-lippman.png'
heading Marc Lippman, MD
heading
heading Board Members
image, url='https://catenabio.com/wp-content/uploads/2023/10/matt-francis-final.png'
heading Matt Francis, PhD
image, url='https://catenabio.com/wp-content/uploads/2023/09/marco-lobba-1.png'
heading Marco Lobba, PhD
image, url='https://catenabio.com/wp-content/uploads/2023/09/chinmaya-rath.png'
heading Chinmaya Rath
image, url='https://catenabio.com/wp-content/themes/catena/images/team-1.png'
heading We’re Going Beyond the Current Limits of Biology
link Explore the science, url='https://catenabio.com/science/'
link Get in touch, url='https://catenabio.com/contact/'
contentinfo
link CatenaBio Home, url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo-white.svg'
link, url='https://www.linkedin.com/company/catena-biosciences/'
link About Us, url='https://catenabio.com/about-us/'
link Science, url='https://catenabio.com/science/'
link Pipeline, url='https://catenabio.com/pipeline/'
link Investors + Partners, url='https://catenabio.com/investors-partners/'
link News + Publications, url='https://catenabio.com/news-publications/'
link Privacy Policy, url='https://catenabio.com/privacy-policy/'
link Terms + Conditions, url='https://catenabio.com/terms-conditions/'
link Contact Us, url='https://catenabio.com/contact/'
paragraph
StaticText Catenase, CysTyr, C-Y Bond, and Multi-Payload Conjugate are trademarks of CatenaBio. Other trademarks are property of their respective owners.
paragraph
StaticText © 2025 CatenaBio. All Rights Reserved.
Reasoning for action: By clicking on the About Us link, I will be taken to a page specifically dedicated to providing insights into CatenaBio's mission, values, and general company background. This is crucial for understanding the company's perspective and how it aligns with my needs as a customer interested in innovative biotech solutions, particularly regarding their approach to antibody-drug conjugates.
Action: click(91) # Click on the About Us link to learn more about the company.
Change Description: After clicking the 'About Us' link, the browser state transitioned from the CatenaBio homepage to the About Us page, updating the main content to include new headings, paragraphs discussing the technology, team members, and the company's origins, while maintaining the same alert banner and navigation structure.
Screenshot before:Screenshot after:---
Step 2:
Url (before/after):
https://catenabio.com/about-us/
https://catenabio.com/science/
Content (before/after):
RootWebArea About Us - CatenaBio, focused, url='https://catenabio.com/about-us/'
banner
paragraph
StaticText Alert:
StaticText Unauthorized individuals have been falsely claiming to represent CatenaBio.
Show more
[58] link Learn more, center=(1324,30), inner_text=Learn more , url='https://catenabio.com/contact#alert'
[62] link CatenaBio Home, center=(193,94), url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo.svg'
link Skip to content, url='https://catenabio.com/about-us/#content'
[69] link Contact Us, center=(1782,94), url='https://catenabio.com/contact/'
navigation
list
listitem
[89] link About Us, center=(392,161), url='https://catenabio.com/about-us/'
listitem
[91] link Science, center=(629,158), url='https://catenabio.com/science/'
listitem
[93] link Pipeline, center=(857,158), url='https://catenabio.com/pipeline/'
listitem
[95] link Investors + Partners, center=(1141,158), url='https://catenabio.com/investors-partners/'
listitem
[97] link News + Publications, center=(1482,158), url='https://catenabio.com/news-publications/'
heading Game-Changing Biomolecule Synthesis
paragraph
StaticText Developed in the same halls where CRISPR was created, CatenaBio’s technology enables the fusion of proteins with the 3-dimensional control that only previously existed with small molecule synthesis. The result is the ability to synthesize novel biomolecules in any structure, combination, or orientation—the only limitation is imagination.
paragraph
StaticText We foresee the impact of our bioconjugation approach extending across therapeutic areas; it may even have consumer applications.
paragraph
StaticText The core of CatenaBio’s technology results from an exhaustive search of the microbial kingdom for a robust enzyme with broad effectiveness. The patented Catenase
superscript
StaticText ™
StaticText technology enables biomolecules to be fused at naturally occurring amino acids—tyrosine and cysteine—under gentle reaction conditions that optimize novel biomolecule yield.
image, url='https://catenabio.com/wp-content/themes/catena/images/blue-yellow-logo-dist-rec.svg'
heading Originating From Berkeley Labs
paragraph
StaticText Our science is invented by the top minds at UC Berkeley
image, url='https://catenabio.com/wp-content/themes/catena/images/jennifer-doudna.png'
heading Professor Jennifer Doudna, PhD
heading Inventor | 2020 Nobel Prize Laureate – Chemistry
image, url='https://catenabio.com/wp-content/themes/catena/images/matt-francis-final.png'
heading Professor Matt Francis, PhD
heading Inventor | Chair of the UC Berkeley Department of Chemistry
heading Meet the Visionaries Behind the Science
heading Leadership Team
image, url='https://catenabio.com/wp-content/themes/catena/images/team/final/saurabh-johri.png'
heading Saurabh Johri
paragraph
StaticText Chief Business Officer
image, url='https://catenabio.com/wp-content/themes/catena/images/team/final/rick-kendall.png'
heading Rick Kendall, PhD
paragraph
StaticText Chief Science Officer
image, url='https://catenabio.com/wp-content/themes/catena/images/team/final/marco-lobba.png'
heading Marco Lobba, PhD
paragraph
StaticText CEO and Co-founder
heading Scientific Advisors
image, url='https://catenabio.com/wp-content/uploads/2023/10/matt-francis-final.png'
heading Matt Francis, PhD
heading
image, url='https://catenabio.com/wp-content/uploads/2023/09/john-delaney.png'
heading John Delaney, PhD
heading
image, url='https://catenabio.com/wp-content/uploads/2023/09/marc-lippman.png'
heading Marc Lippman, MD
heading
heading Board Members
image, url='https://catenabio.com/wp-content/uploads/2023/10/matt-francis-final.png'
heading Matt Francis, PhD
image, url='https://catenabio.com/wp-content/uploads/2023/09/marco-lobba-1.png'
heading Marco Lobba, PhD
image, url='https://catenabio.com/wp-content/uploads/2023/09/chinmaya-rath.png'
heading Chinmaya Rath
image, url='https://catenabio.com/wp-content/themes/catena/images/team-1.png'
heading We’re Going Beyond the Current Limits of Biology
link Explore the science, url='https://catenabio.com/science/'
link Get in touch, url='https://catenabio.com/contact/'
contentinfo
link CatenaBio Home, url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo-white.svg'
link, url='https://www.linkedin.com/company/catena-biosciences/'
link About Us, url='https://catenabio.com/about-us/'
link Science, url='https://catenabio.com/science/'
link Pipeline, url='https://catenabio.com/pipeline/'
link Investors + Partners, url='https://catenabio.com/investors-partners/'
link News + Publications, url='https://catenabio.com/news-publications/'
link Privacy Policy, url='https://catenabio.com/privacy-policy/'
link Terms + Conditions, url='https://catenabio.com/terms-conditions/'
link Contact Us, url='https://catenabio.com/contact/'
paragraph
StaticText Catenase, CysTyr, C-Y Bond, and Multi-Payload Conjugate are trademarks of CatenaBio. Other trademarks are property of their respective owners.
paragraph
StaticText © 2025 CatenaBio. All Rights Reserved.
RootWebArea Science - CatenaBio, focused, url='https://catenabio.com/science/'
banner
paragraph
StaticText Alert:
StaticText Unauthorized individuals have been falsely claiming to represent CatenaBio.
Show more
[58] link Learn more, center=(1324,30), inner_text=Learn more , url='https://catenabio.com/contact#alert'
[62] link CatenaBio Home, center=(193,94), url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo.svg'
link Skip to content, url='https://catenabio.com/science/#content'
[69] link Contact Us, center=(1782,94), url='https://catenabio.com/contact/'
navigation
list
listitem
[89] link About Us, center=(389,158), url='https://catenabio.com/about-us/'
listitem
[91] link Science, center=(626,161), url='https://catenabio.com/science/'
listitem
[93] link Pipeline, center=(857,158), url='https://catenabio.com/pipeline/'
listitem
[95] link Investors + Partners, center=(1141,158), url='https://catenabio.com/investors-partners/'
listitem
[97] link News + Publications, center=(1482,158), url='https://catenabio.com/news-publications/'
heading Explore the Future of Protein Conjugation
paragraph
StaticText CatenaBio was founded to develop novel therapeutics by forming never-before-possible structures enabled by our technology, which can modify and combine proteins with complete freedom.
paragraph
StaticText We have developed the
StaticText CysTyr
superscript
StaticText ™
StaticText platform utilizing the novel
StaticText Catenase
superscript
StaticText ™
StaticText enzyme, engineered to activate tyrosine residues with cysteine residues to form our proprietary
StaticText C-Y Bond
superscript
StaticText ™
StaticText .
paragraph
StaticText Our platform redefines what therapeutics are possible, by removing longstanding limitations on the size, number, and type of molecules that can be attached to a single protein.
heading Imagine if you could...
image ADC connected to a therapeutic, url='https://catenabio.com/wp-content/themes/catena/images/science-mol-1-nc.svg'
paragraph
StaticText Take any antibody-drug conjugate and add
StaticText additional therapeutic modalities
paragraph
StaticText Take any antibody and
StaticText attach functional cytokines
image Antibody with functional cytokines attached, url='https://catenabio.com/wp-content/themes/catena/images/science-mol-2-nc.svg'
image Cell attached to a protein, url='https://catenabio.com/wp-content/themes/catena/images/science-mol-3-nc.svg'
paragraph
StaticText Attach a targeting protein to the surface of any cell
StaticText without genetic editing
image, url='https://catenabio.com/wp-content/themes/catena/images/blue-logo-dist-home.png'
heading Imagine what CatenaBio could do for you.
link Collaborate with us, url='https://catenabio.com/investors-partners/'
heading Advantages of Our Innovative Platform
paragraph
StaticText CatenaBio's technology is significantly differentiated from other approaches.
paragraph
StaticText Simplicity –
StaticText Conventionally purified proteins can be fused under gentle, physiological reaction conditions that maintain secondary structure and enzymatic activity. The only oxidizer is the oxygen dissolved in the reaction, eliminating the need for harsh reagents and extensive reaction cleanup.
paragraph
StaticText Stability –
StaticText The resulting covalent linkage between proteins is more stable than those made with maleimide chemistries.
paragraph
StaticText Selectivity –
StaticText The Catenase activation step leaves active-site residues intact, resulting in highly specific conjugations of proteins at defined positions and/or orientations.
paragraph
StaticText Scalability –
StaticText Partnerships with 2 large pharmaceutical companies have demonstrated gram quantity syntheses and linear scalability over a 30,000x range in production.
table
rowgroup
row
cell
cell Simplicity
cell Stability
cell Selectivity
cell Scalability
row
cell C-Y Bond CysTyr Platform
image, url='https://catenabio.com/wp-content/themes/catena/images/logo-dist-sm.svg'
paragraph
paragraph
cell Native amino acids in physiological conditions
paragraph
cell Highly stable
paragraph
cell Highly selective; specific conjugations
paragraph
cell High yields and throughput
paragraph
row
cell Artificial Amino Acids Click Chemistry
paragraph
paragraph
cell Must reengineer metabolism of cells to incorporate artificial amino acids
paragraph
cell Highly stable
paragraph
cell Highly selective; must add artificial reactive group to both molecules in reaction
paragraph
cell Significant barriers to production due to low yields and high cost to synthesize strained cyclooctyne reagents
paragraph
row
cell Cysteine-X Maleimide Chemistry
paragraph
paragraph
cell Difficult; can’t make protein-protein bonds
paragraph
cell Not stable
paragraph
cell Selective
paragraph
cell Low yields
paragraph
row
cell Lysine-X Amide Bond
paragraph
paragraph
cell Unstable reagents
paragraph
cell Highly stable
paragraph
cell Not selective to specific lysine
paragraph
cell Requires organic solvents
paragraph
image, url='https://catenabio.com/wp-content/themes/catena/images/science-config-2.svg'
heading Any Protein—Many Configurations
paragraph
StaticText CatenaBio’s technology lets you connect to any site on a protein just by moving the cysteine using the same tools that have been in use for decades. This allows for precise control of the geometry of your therapeutic.
heading Proof of Principle
paragraph
StaticText Explore our transformative publications.
link See the latest, url='https://catenabio.com/news-publications/#publications'
heading Next Generation Antibody Drug Conjugates: Multi-Payload Conjugates targeting multiple mechanisms of cell killing
paragraph
StaticText April 8, 2024
link, url='https://catenabio.com/wp-content/themes/catena/pdfs/aacr-poster-2024.pdf'
heading CATENABIO: Therapeutics limited only by imagination
paragraph
StaticText November 6, 2023
link, url='https://catenabio.com/wp-content/themes/catena/pdfs/adc-conference-poster-2023-san-diego.pdf'
heading Modification of Cysteine-Substituted Antibodies Using Enzymatic Oxidative Coupling Reactions
paragraph
StaticText February 14, 2023
link, url='https://pubs.acs.org/doi/10.1021/acs.bioconjchem.2c00576'
contentinfo
link CatenaBio Home, url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo-white.svg'
link, url='https://www.linkedin.com/company/catena-biosciences/'
link About Us, url='https://catenabio.com/about-us/'
link Science, url='https://catenabio.com/science/'
link Pipeline, url='https://catenabio.com/pipeline/'
link Investors + Partners, url='https://catenabio.com/investors-partners/'
link News + Publications, url='https://catenabio.com/news-publications/'
link Privacy Policy, url='https://catenabio.com/privacy-policy/'
link Terms + Conditions, url='https://catenabio.com/terms-conditions/'
link Contact Us, url='https://catenabio.com/contact/'
paragraph
StaticText Catenase, CysTyr, C-Y Bond, and Multi-Payload Conjugate are trademarks of CatenaBio. Other trademarks are property of their respective owners.
paragraph
StaticText © 2025 CatenaBio. All Rights Reserved.
Reasoning for action: I chose to click on the Science link because it is a key section that provides insights into CatenaBio's innovative scientific methods and technologies, particularly in relation to antibody-drug conjugate technologies. This aligns perfectly with the user story, as understanding the scientific framework is essential for evaluating whether their offerings match my interests.
Action: click(91) # Click on the Science link to learn more about CatenaBio's scientific approach.
Change Description: The browser changed from displaying the 'About Us' page of CatenaBio to the 'Science' page, providing information about the company's scientific approach and innovative protein conjugation technologies, while maintaining the previously displayed banner alert and navigation links.
Screenshot before:Screenshot after:---
Step 3:
Url (before/after):
https://catenabio.com/science/
https://catenabio.com/pipeline/
Content (before/after):
RootWebArea Science - CatenaBio, focused, url='https://catenabio.com/science/'
banner
paragraph
StaticText Alert:
StaticText Unauthorized individuals have been falsely claiming to represent CatenaBio.
Show more
[58] link Learn more, center=(1324,30), inner_text=Learn more , url='https://catenabio.com/contact#alert'
[62] link CatenaBio Home, center=(193,94), url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo.svg'
link Skip to content, url='https://catenabio.com/science/#content'
[69] link Contact Us, center=(1782,94), url='https://catenabio.com/contact/'
navigation
list
listitem
[89] link About Us, center=(389,158), url='https://catenabio.com/about-us/'
listitem
[91] link Science, center=(626,161), url='https://catenabio.com/science/'
listitem
[93] link Pipeline, center=(857,158), url='https://catenabio.com/pipeline/'
listitem
[95] link Investors + Partners, center=(1141,158), url='https://catenabio.com/investors-partners/'
listitem
[97] link News + Publications, center=(1482,158), url='https://catenabio.com/news-publications/'
heading Explore the Future of Protein Conjugation
paragraph
StaticText CatenaBio was founded to develop novel therapeutics by forming never-before-possible structures enabled by our technology, which can modify and combine proteins with complete freedom.
paragraph
StaticText We have developed the
StaticText CysTyr
superscript
StaticText ™
StaticText platform utilizing the novel
StaticText Catenase
superscript
StaticText ™
StaticText enzyme, engineered to activate tyrosine residues with cysteine residues to form our proprietary
StaticText C-Y Bond
superscript
StaticText ™
StaticText .
paragraph
StaticText Our platform redefines what therapeutics are possible, by removing longstanding limitations on the size, number, and type of molecules that can be attached to a single protein.
heading Imagine if you could...
image ADC connected to a therapeutic, url='https://catenabio.com/wp-content/themes/catena/images/science-mol-1-nc.svg'
paragraph
StaticText Take any antibody-drug conjugate and add
StaticText additional therapeutic modalities
paragraph
StaticText Take any antibody and
StaticText attach functional cytokines
image Antibody with functional cytokines attached, url='https://catenabio.com/wp-content/themes/catena/images/science-mol-2-nc.svg'
image Cell attached to a protein, url='https://catenabio.com/wp-content/themes/catena/images/science-mol-3-nc.svg'
paragraph
StaticText Attach a targeting protein to the surface of any cell
StaticText without genetic editing
image, url='https://catenabio.com/wp-content/themes/catena/images/blue-logo-dist-home.png'
heading Imagine what CatenaBio could do for you.
link Collaborate with us, url='https://catenabio.com/investors-partners/'
heading Advantages of Our Innovative Platform
paragraph
StaticText CatenaBio's technology is significantly differentiated from other approaches.
paragraph
StaticText Simplicity –
StaticText Conventionally purified proteins can be fused under gentle, physiological reaction conditions that maintain secondary structure and enzymatic activity. The only oxidizer is the oxygen dissolved in the reaction, eliminating the need for harsh reagents and extensive reaction cleanup.
paragraph
StaticText Stability –
StaticText The resulting covalent linkage between proteins is more stable than those made with maleimide chemistries.
paragraph
StaticText Selectivity –
StaticText The Catenase activation step leaves active-site residues intact, resulting in highly specific conjugations of proteins at defined positions and/or orientations.
paragraph
StaticText Scalability –
StaticText Partnerships with 2 large pharmaceutical companies have demonstrated gram quantity syntheses and linear scalability over a 30,000x range in production.
table
rowgroup
row
cell
cell Simplicity
cell Stability
cell Selectivity
cell Scalability
row
cell C-Y Bond CysTyr Platform
image, url='https://catenabio.com/wp-content/themes/catena/images/logo-dist-sm.svg'
paragraph
paragraph
cell Native amino acids in physiological conditions
paragraph
cell Highly stable
paragraph
cell Highly selective; specific conjugations
paragraph
cell High yields and throughput
paragraph
row
cell Artificial Amino Acids Click Chemistry
paragraph
paragraph
cell Must reengineer metabolism of cells to incorporate artificial amino acids
paragraph
cell Highly stable
paragraph
cell Highly selective; must add artificial reactive group to both molecules in reaction
paragraph
cell Significant barriers to production due to low yields and high cost to synthesize strained cyclooctyne reagents
paragraph
row
cell Cysteine-X Maleimide Chemistry
paragraph
paragraph
cell Difficult; can’t make protein-protein bonds
paragraph
cell Not stable
paragraph
cell Selective
paragraph
cell Low yields
paragraph
row
cell Lysine-X Amide Bond
paragraph
paragraph
cell Unstable reagents
paragraph
cell Highly stable
paragraph
cell Not selective to specific lysine
paragraph
cell Requires organic solvents
paragraph
image, url='https://catenabio.com/wp-content/themes/catena/images/science-config-2.svg'
heading Any Protein—Many Configurations
paragraph
StaticText CatenaBio’s technology lets you connect to any site on a protein just by moving the cysteine using the same tools that have been in use for decades. This allows for precise control of the geometry of your therapeutic.
heading Proof of Principle
paragraph
StaticText Explore our transformative publications.
link See the latest, url='https://catenabio.com/news-publications/#publications'
heading Next Generation Antibody Drug Conjugates: Multi-Payload Conjugates targeting multiple mechanisms of cell killing
paragraph
StaticText April 8, 2024
link, url='https://catenabio.com/wp-content/themes/catena/pdfs/aacr-poster-2024.pdf'
heading CATENABIO: Therapeutics limited only by imagination
paragraph
StaticText November 6, 2023
link, url='https://catenabio.com/wp-content/themes/catena/pdfs/adc-conference-poster-2023-san-diego.pdf'
heading Modification of Cysteine-Substituted Antibodies Using Enzymatic Oxidative Coupling Reactions
paragraph
StaticText February 14, 2023
link, url='https://pubs.acs.org/doi/10.1021/acs.bioconjchem.2c00576'
contentinfo
link CatenaBio Home, url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo-white.svg'
link, url='https://www.linkedin.com/company/catena-biosciences/'
link About Us, url='https://catenabio.com/about-us/'
link Science, url='https://catenabio.com/science/'
link Pipeline, url='https://catenabio.com/pipeline/'
link Investors + Partners, url='https://catenabio.com/investors-partners/'
link News + Publications, url='https://catenabio.com/news-publications/'
link Privacy Policy, url='https://catenabio.com/privacy-policy/'
link Terms + Conditions, url='https://catenabio.com/terms-conditions/'
link Contact Us, url='https://catenabio.com/contact/'
paragraph
StaticText Catenase, CysTyr, C-Y Bond, and Multi-Payload Conjugate are trademarks of CatenaBio. Other trademarks are property of their respective owners.
paragraph
StaticText © 2025 CatenaBio. All Rights Reserved.
RootWebArea Pipeline - CatenaBio, focused, url='https://catenabio.com/pipeline/'
banner
paragraph
StaticText Alert:
StaticText Unauthorized individuals have been falsely claiming to represent CatenaBio.
Show more
[58] link Learn more, center=(1324,30), inner_text=Learn more , url='https://catenabio.com/contact#alert'
[62] link CatenaBio Home, center=(193,94), url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo.svg'
link Skip to content, url='https://catenabio.com/pipeline/#content'
[69] link Contact Us, center=(1782,94), url='https://catenabio.com/contact/'
navigation
list
listitem
[89] link About Us, center=(389,158), url='https://catenabio.com/about-us/'
listitem
[91] link Science, center=(623,158), url='https://catenabio.com/science/'
listitem
[93] link Pipeline, center=(854,161), url='https://catenabio.com/pipeline/'
listitem
[95] link Investors + Partners, center=(1141,158), url='https://catenabio.com/investors-partners/'
listitem
[97] link News + Publications, center=(1482,158), url='https://catenabio.com/news-publications/'
heading Our Pipeline Reimagines Antibody-Drug Conjugates
heading We’re Focused on Transforming Antibody Therapeutics With Multi-Payload Conjugate™ Technology
superscript
paragraph
StaticText CatenaBio is developing
StaticText Multi-Payload Conjugate
StaticText (
StaticText MPC
StaticText ) technology by combining two payloads with different mechanisms of action (MOAs) on a single antibody.
heading Rationale
paragraph
StaticText Single-MOA payload is an enormous limitation of current antibody-drug conjugates (ADCs)
heading Key Advantage
paragraph
StaticText We can create
StaticText MPCs
StaticText unobtainable by existing means
heading Indication
paragraph
StaticText Solid tumors
image, url='https://catenabio.com/wp-content/themes/catena/images/molecule-link-2.svg'
heading Lead Assets
image CATB-101, url='https://catenabio.com/wp-content/themes/catena/images/pipeline-catb-1.svg'
paragraph
StaticText Validated antibody with two mechanistically distinct therapeutic payloads
image CATB-102, url='https://catenabio.com/wp-content/themes/catena/images/pipeline-catb-2.svg'
paragraph
StaticText Undisclosed novel MPC
heading We're Revolutionizing Therapeutics
link Discover our vision, url='https://catenabio.com/investors-partners/'
contentinfo
link CatenaBio Home, url='https://catenabio.com/'
image CatenaBio Home, url='https://catenabio.com/wp-content/themes/catena/images/catena-logo-white.svg'
link, url='https://www.linkedin.com/company/catena-biosciences/'
link About Us, url='https://catenabio.com/about-us/'
link Science, url='https://catenabio.com/science/'
link Pipeline, url='https://catenabio.com/pipeline/'
link Investors + Partners, url='https://catenabio.com/investors-partners/'
link News + Publications, url='https://catenabio.com/news-publications/'
link Privacy Policy, url='https://catenabio.com/privacy-policy/'
link Terms + Conditions, url='https://catenabio.com/terms-conditions/'
link Contact Us, url='https://catenabio.com/contact/'
paragraph
StaticText Catenase, CysTyr, C-Y Bond, and Multi-Payload Conjugate are trademarks of CatenaBio. Other trademarks are property of their respective owners.
paragraph
StaticText © 2025 CatenaBio. All Rights Reserved.
Reasoning for action: I reasoned that accessing the Pipeline page is crucial to fulfilling the user story, as it directly addresses the requirement to understand CatenaBio's current projects. This page will likely provide insights into the latest developments and how they align with the user's interests in innovative biotech solutions, particularly in the area of antibody-drug conjugates.
Action: click(93) # Click on the Pipeline link to learn more about CatenaBio's current projects and developments.
Change Description: The browser transitioned from displaying the Science page of CatenaBio to the Pipeline page, showcasing information about CatenaBio's current projects and developments in antibody-drug conjugate technology. The page now features new headings and content related to the company's Multi-Payload Conjugate technology and lead assets, reflecting the focus on transforming antibody therapeutics.
Screenshot before:Screenshot after:---